RBC Capital Markets analyst Paul Quinn has hiked his rating on shares of Louisiana-Pacific to ‘outperform’ from ‘sector perform.’ Quinn also has bumped up his price target to $19 from $16 for LP, which opened this morning (Ticker: LPX) at $16.06. Quinn’s main reason is the positive price trends for the Nashville-based company’s core oriented strand board products: He notes that prices have risen by double-digit percentage points over the past five weeks.
Leerink Swann analyst Ana Gupte has launched coverage of Acadia Healthcare with an 'outperform' rating and a $90 price target that gives investors 25 percent of upside from where the shares (Ticker: ACHC) closed on Tuesday. She sees the Franklin-based company beating the Street's consensus EBITDA numbers both this year and next.
Following Dollar General's second-quarter earnings report, UBS' Michael Lasser has taken a sanguine tone that is similar to that of a number of other analysts. In reiterating his 'buy' rating and $85 target for Dollar General (Ticker: DG), Lasser says CEO Todd Vasos and his team still have a number of ways to hit their profit growth goals.
From here, even if the company's algorithm rests on a longer-term comp that hovers around the 3% range, we think it can still produce mid-teens EPS growth with optionality to the upside. We would use the pullback as an opportunity.
A number of analysts have tweaked their price targets for shares of Dollar General following the company’s second-quarter profit report, which investors met with a good bit of antipathy. Most of the Street moves so far have been positive, though: Scott Ciccarelli at RBC Capital has taken his target to $88 from $86 — Dollar General (Ticker: DG) is changing hands this morning around $74 — and Matt Boss at JPMorgan Chase is even more upbeat, having taken his target to $90 from $87.
Paul Trussell at Deutsche Bank is a little less upbeat — even though he is keeping his ‘buy’ rating — and has tweaked his target to $84 from $85. And Meredith Adler at Barclays is even less optimistic. She has an ‘equal weight’ rafting on Dollar General and, with a $76 target (up from $74), still sees the stock going nowhere for a while.
Stifel Nicolaus analyst Dan Bernstein has upgraded shares of Healthcare Realty Trust to 'buy' from 'hold,' saying the Nashville-based REIT is a good value for investors to step in after it slipped from above to $25 to below $23 in the recent market swoon. Bernstein sees more than 20 percent upside for Healthcare Realty (Ticker: HR), which was changing hands at almost $23.20 Wednesday afternoon. Read more here.
The equity research team at RBC Capital Markets says investors should stay in (or get back into) many of the names that were doing well before the market's recent slide. Among these "market darlings," they say, is Nashville-based HCA Holdings, which has fallen 10 percent in the past month — right in line with the S&P 500 Index. HCA (Ticker HCA) fell 1.7 percent Tuesday to $83.09.
Veteran bank analyst Peyton Green has moved from Sterne Agee to Piper Jaffray, where he has now resumed coverage of Pinnacle Financial Partners, among other regional banks. Green rates shares of downtown-based Pinnacle at 'neutral' and sees them climbing to $53 in the coming quarters. The stock (Ticker: PNFP) closed Monday's volatile session down almost 6 percent at $45.91.
Analyst Brian Tanquilut at Jefferies & Co. sees many bright days ahead for Acadia Healthcare investors. Following the company's second-quarter earnings report, he has raised his price target for the stock to $100 from $88. That leaves a lot of upside: Acadia (Ticker: ACHC) closed last week's trading at $81.02 and is to $81.84 this afternoon.
Just as the dust is settling on the second-quarter earnings season, John Ransom at Raymond James has raised his rating on shares of Community Health Systems to 'outperform' from 'market perform.' He had gone in the other direction following the Supreme Court's Obamacare ruling in June, but the stock has since retreated near to pre-ruling levels. His new price target for the stock is $70. It was changing hands Friday morning (Ticker: CYH) at about $57.60.
Another analyst has weighed in on the prospects for shares of National Health Investors following word of the pending exit of CEO Justin Hutchens. And just like Juan Sanabria at Bank of America Merrill Lynch, John Kim at BMO Capital Markets says Hutchens' departure is a blow for NHI. He sees "very little managerial depth" at the Murfreesboro-based company and has lowered his rating on the company to 'market perform' from 'outperform.' He also has trimmed his price target more than 10 percent to $65. NHI (Ticker: NHI) is trading at about $58.50.
Bank of America Merrill Lynch analyst Juan Sanabria is a little unsettled by the looming and unexpected departure at National Health Investors of CEO Justin Hutchens. Sanabria on Tuesday downgraded shares of the Murfreesboro-based real estate investment trust to ‘underperform’ from ‘neutral,’ saying Hutchens’ exit creates added uncertainty. NHI shares (Ticker: NHI) slipped a bit Wednesday to $59.29. So far this year, they’re down about 15 percent.
POSTDATA: WARRANTY DEEDS